ImmuONE develops a 3D human lung model that enables companies to replace or reduce the need for animal testing. Its platform supports respiratory safety tests and more complex immunology assays that show long-term effects of substances on the lung, including potential to cause inflammation. The company serves consumer products and pharmaceutical customers and has recently taken on clients in the chemicals sector. ImmuONE plans to use the newly raised funds to develop its capabilities, target new sectors such as agrichemicals and automotive, and expand its team. It intends to hire two new scientists as part of that expansion. The company raised £600K in this round to support those developments. ImmunONE has developed a laboratory-grown 3D human lower lung tissue and immune-cell model that assesses the safety of drugs, chemicals and cosmetics without using animals. The model enables testing of small airways and lung inflammation, producing results that are more reliable and reproducible than animal tests or invasive lung‑scraping. The technology was developed by Dr Abigail Martin during her PhD and the company was founded with Professor Victoria Hutter in 2019. ImmunONE serves around 20 customers globally, including blue‑chip chemical and consumer‑products companies, and has generated over £1m in revenue since its launch two years ago. The company plans to use the funds to move into new headquarters in Milton Keynes, open new laboratories in Stevenage to expand capacity, continue R&D, grow the team and create six new jobs. ImmunONE is based in Hatfield, UK.

Total raised

$3M

Funding rounds

2

Latest round

Equity

Latest activity

Mar 2025